GAYANEH GHARAKHANI: Open Payments
NPI 1124638663 · GLENDALE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,090 in 37 payments from 11 companies in 2025. Trend: 2023 $162 · 2024 $710 · 2025 $1,090
Food & beverage: $1,090
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 6 | $246 |
| Janssen Biotech, Inc. | 13 | $209 |
| Ardelyx, Inc. | 2 | $155 |
| Lilly USA, LLC | 1 | $106 |
| ABBVIE INC. | 3 | $96 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $79 |
| Celltrion USA Inc. | 2 | $60 |
| QOL Medical, LLC | 2 | $46 |
| Aimmune Therapeutics, Inc. | 2 | $44 |
| Novo Nordisk Inc | 1 | $31 |
Products named: REZDIFFRA, TREMFYA, IBSRELA, OMVOH, XIFAXAN, LINZESS, VEGZELMA, Sucraid.
Industry payments across CA — which companies pay providers there.
